Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $37.60 in the last session, down -2.62% from day before closing price of $38.61. In other words, the price has decreased by -$2.62 from its previous closing price. On the day, 3.09 million shares were traded.
Ratios:
We take a closer look at SRPT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.46 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.18.
On April 11, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $115.
H.C. Wainwright Upgraded its Sell to Neutral on April 02, 2025, while the target price for the stock was maintained at $75.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.65 while its Price-to-Book (P/B) ratio in mrq is 3.23.
Stock Price History:
Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $34.10. The 50-Day Moving Average of the stock is -28.87%, while the 200-Day Moving Average is calculated to be -63.67%.
Shares Statistics:
A total of 98.25M shares are outstanding, with a floating share count of 93.37M. Insiders hold about 4.99% of the company’s shares, while institutions hold 90.29% stake in the company.
Earnings Estimates
A comprehensive evaluation of Sarepta Therapeutics Inc (SRPT) is underway, with the input of 12.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $1.11, with high estimates of $2.11 and low estimates of -$0.35.
Analysts are recommending an EPS of between $2.82 and -$3.63 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $7.85, with 13.0 analysts recommending between $12.74 and $1.67.
Revenue Estimates
According to 18 analysts, the current quarter’s revenue is expected to be $558.94M. It ranges from a high estimate of $646.48M to a low estimate of $526.98M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $362.93MFor the next quarter, 18 analysts are estimating revenue of $608.35M. There is a high estimate of $780.1M for the next quarter, whereas the lowest estimate is $538.41M.
A total of 21 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.82B, while the lowest revenue estimate was $2.36B, resulting in an average revenue estimate of $2.56B. In the same quarter a year ago, actual revenue was $1.9BBased on 22 analysts’ estimates, the company’s revenue will be $2.96B in the next fiscal year. The high estimate is $3.88B and the low estimate is $2.33B.
